Frederik Mølgaard  Nielsen

Frederik Mølgaard Nielsen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
NHNicolai Haase
Nicolai Haase
RPRonni Plovsing
Ronni Plovsing
SCSteffen Christensen
Steffen Christensen
LPLone M. Poulsen
Lone M. Poulsen
ABAnne C. Brøchner
Anne C. Brøchner
APAnders Perner
Anders Perner
Background: Characteristics and care of intensive care unit (ICU) patients with COVID‐19 may have changed during the pandemic, but longitudinal data assessing this are limited. We compared patients with COVID‐19 admitted to Danish ICUs in the first wave with those admitted later.Methods: Among all Danish ICU patients with COVID‐19, we compared demographics, chronic comorbidities, use of organ support, length of stay and vital status of those admitted 10 March to 19 May 2020 (first wave) versus 20 May 2020 to 30 June 2021. We analysed risk factors for death by adjusted logistic regression analysis.Results: Among all hospitalised patients with COVID‐19, a lower proportion was admitted to ICU after the first wave (13% vs. 8%). Among all 1374 ICU patients with COVID‐19, 326 were admitted during the first wave. There were no major differences in patient's characteristics or mortality between the two periods, but use of invasive mechanical ventilation (81% vs. 58% of patients), renal replacement therapy (26% vs. 13%) and ECMO (8% vs. 3%) and median length of stay in ICU (13 vs. 10 days) and in hospital (20 vs. 17 days) were all significantly lower after the first wave. Risk factors for death were higher age, larger burden of comorbidities (heart failure, pulmonary disease and kidney disease) and active cancer, but not admission during or after the first wave.Conclusions: After the first wave of COVID‐19 in Denmark, a lower proportion of hospitalised patients with COVID‐19 were admitted to ICU. Among ICU patients, use of organ support was lower and length of stay was reduced, but mortality rates remained at a relatively high level.

7 July 2022 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
ECElena Crescioli
Elena Crescioli
KKKirsten Uldal Krejberg
Kirsten Uldal Krejberg
TKThomas Lass Klitgaard
Thomas Lass Klitgaard
FNFrederik Mølgaard Nielsen
Frederik Mølgaard Nielsen
MBMarija Barbateskovic
Marija Barbateskovic
BRBodil Steen Rasmussen
Bodil Steen Rasmussen
Background: Oxygen therapy is a common treatment in the intensive care unit (ICU) with both potentially desirable and undesirable long‐term effects. This systematic review aimed to assess the long‐term outcomes of lower versus higher oxygenation strategies in adult ICU survivors.Methods: We included randomised clinical trials (RCTs) comparing lower versus higher oxygen supplementation or oxygenation strategies in adults admitted to the ICU. We searched major electronic databases and trial registers. We included all non‐mortality long‐term outcomes. Prespecified co‐primary outcomes were the long‐term cognitive function measures, the overall score of any valid health‐related quality of life (HRQoL) evaluation, standardised 6‐min walk test, and lung diffusion capacity. The protocol was published and prospectively registered in the PROSPERO database (CRD42021223630).Results: The review included 17 RCTs comprising 6592 patients, and six trials with 825 randomised patients reported one or more outcomes of interest. We observed no difference in cognitive evaluation via Telephone Interview for Cognitive Status (one trial, 409 patients) (mean score: 30.6 ± 4.5 in the lower oxygenation group vs. 30.4 ± 4.3 in the higher oxygenation group). The trial was judged at overall high risk of bias and the certainty of evidence was very low. Any difference was neither observed in HRQoL measured via EuroQol 5 dimensions 5 level questionnaire and EQ Visual Analogue Score (one trial, 499 patients) (mean score: 70.1 ± 22 in the lower oxygenation group vs. 67.6 ± 22.4 in the higher oxygenation group). The trial was judged as having high risk of bias, the certainty of evidence was very low. No trial reported neither the standardised 6‐min walk test nor lung diffusion test.Conclusion: The evidence is very uncertain about the effect of a lower versus a higher oxygenation strategy on both the cognitive function and HRQoL. A lower versus a higher oxygenation strategy may have a little to no effect on both outcomes but the certainty of evidence is very low. No evidence was found for the effects on the standardised 6‐min walking test and diffusion capacity test.

6 November 2022 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
LRLene Russell
Lene Russell
SWSarah Weihe
Sarah Weihe
EMEmilie Kabel Madsen
Emilie Kabel Madsen
CHChristine Lodberg Hvas
Christine Lodberg Hvas
JLJens Wolfgang Leistner
Jens Wolfgang Leistner
APAnders Perner
Anders Perner
Background: Intensive care unit (ICU) patients with Coronavirus disease 2019 (COVID‐19) have an increased risk of thromboembolic complications. We describe the occurrence of thromboembolic and bleeding events in all ICU patients with COVID‐19 in Denmark during the first and second waves of the pandemic.Methods: This was a sub‐study of the Danish Intensive Care Covid database, in which all patients with SARS‐CoV‐2 admitted to Danish ICUs from 10th March 2020 to 30th June 2021 were included. We registered coagulation variables at admission, and all thromboembolic and bleeding events, and the use of heparins during ICU stay. Variables associated with thrombosis and bleeding and any association with 90‐day mortality were estimated using Cox regression analyses.Results: We included 1369 patients in this sub‐study; 158 (12%, 95% confidence interval 10–13) had a thromboembolic event in ICU and 309 (23%, 20–25) had a bleeding event, among whom 81 patients (6%, 4.8–7.3) had major bleeding. We found that mechanical ventilation and increased D‐dimer were associated with thrombosis and mechanical ventilation, low platelet count and presence of haematological malignancy were associated with bleeding. Most patients (76%) received increased doses of thromboprophylaxis during their ICU stay. Thromboembolic events were not associated with mortality in adjusted analysis (hazard ratio 1.35 [0.91–2.01, p = .14], whereas bleeding events were 1.55 [1.18–2.05, p = .002]).Conclusions: Both thromboembolic and bleeding events frequently occurred in ICU patients with COVID‐19. Based on these data, it is not apparent that increased doses of thromboprophylaxis were beneficial.

8 June 2023 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
NMNick Meier
Nick Meier
APAnders Perner
Anders Perner
RPRonni Plovsing
Ronni Plovsing
SCSteffen Christensen
Steffen Christensen
LPLone M. Poulsen
Lone M. Poulsen
NHNicolai Haase
Nicolai Haase
Background: Among ICU patients with COVID‐19, it is largely unknown how the overall outcome and resource use have changed with time, different genetic variants, and vaccination status.Methods: For all Danish ICU patients with COVID‐19 from March 10, 2020 to March 31, 2022, we manually retrieved data on demographics, comorbidities, vaccination status, use of life support, length of stay, and vital status from medical records. We compared patients based on the period of admittance and vaccination status and described changes in epidemiology related to the Omicron variant.Results: Among all 2167 ICU patients with COVID‐19, 327 were admitted during the first (March 10–19, 2020), 1053 during the second (May 20, 2020 to June 30, 2021) and 787 during the third wave (July 1, 2021 to March 31, 2022). We observed changes over the three waves in age (median 72 vs. 68 vs. 65 years), use of invasive mechanical ventilation (81% vs. 58% vs. 51%), renal replacement therapy (26% vs. 13% vs. 12%), extracorporeal membrane oxygenation (7% vs. 3% vs. 2%), duration of invasive mechanical ventilation (median 13 vs. 13 vs. 9 days) and ICU length of stay (median 13 vs. 10 vs. 7 days). Despite these changes, 90‐day mortality remained constant (36% vs. 35% vs. 33%). Vaccination rates among ICU patients were 42% as compared to 80% in society. Unvaccinated versus vaccinated patients were younger (median 57 vs. 73 years), had less comorbidity (50% vs. 78%), and had lower 90‐day mortality (29% vs. 51%). Patient characteristics changed significantly after the Omicron variant became dominant including a decrease in the use of COVID‐specific pharmacological agents from 95% to 69%.Conclusions: In Danish ICUs, the use of life support declined, while mortality seemed unchanged throughout the three waves of COVID‐19. Vaccination rates were lower among ICU patients than in society, but the selected group of vaccinated patients admitted to the ICU still had very severe disease courses. When the Omicron variant became dominant a lower fraction of SARS‐CoV‐2 positive patients received COVID treatment indicating other causes for ICU admission.

11 July 2024 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
FNFrederik Mølgaard Nielsen
Frederik Mølgaard Nielsen
TKThomas L. Klitgaard
Thomas L. Klitgaard
NBNiels Henrik Bruun
Niels Henrik Bruun
MMMorten H. Møller
Morten H. Møller
OSOlav L. Schjørring
Olav L. Schjørring
BRBodil S. Rasmussen
Bodil S. Rasmussen
Purpose Optimal oxygenation targets for patients with acute hypoxemic respiratory failure in the intensive care unit (ICU) are not clearly defined due to substantial variability in design of previous trials. This study aimed to perform a pre-specified individual patient data meta-analysis of the Handling Oxygenation Targets in the ICU (HOT-ICU) and the Handling Oxygenation Targets in coronavirus disease 2019 (COVID-19) (HOT-COVID) trials to compare targeting a partial pressure of arterial oxygen (PaO2) of 8–12 kPa in adult ICU patients, assessing both benefits and harms. Methods We assessed 90-day all-cause mortality and days alive without life support in 90 days using a generalised mixed model. Heterogeneity of treatment effects (HTE) was evaluated in 14 subgroups, and results graded using the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN). Results At 90 days, mortality was 40.4% (724/1792) in the 8 kPa group and 40.9% (733/1793) in the 12 kPa group (risk ratio, 0.99; 95% confidence interval [CI] 0.92–1.07; P = 0.80). No difference was observed in number of days alive without life support. Subgroup analyses indicated more days alive without life support in COVID-19 patients targeting 8 kPa (P = 0.04) (moderate credibility), and lower mortality (P = 0.03) and more days alive without life support (P = 0.02) in cancer-patients targeting 12 kPa (low credibility). Conclusion This study reported no overall differences comparing a PaO2 target of 8–12 kPa on mortality or days alive without life support in 90 days. Subgroup analyses suggested HTE in patients with COVID-19 (moderate credibility) and cancer (low credibility).

12 August 2021 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
FNFrederik Mølgaard Nielsen
Frederik Mølgaard Nielsen
TKThomas Lass Klitgaard
Thomas Lass Klitgaard
ECElena Crescioli
Elena Crescioli
SASøren Rosborg Aagaard
Søren Rosborg Aagaard
AAAnne Sofie Andreasen
Anne Sofie Andreasen
BRBodil Steen Rasmussen
Bodil Steen Rasmussen
Background: Coronavirus disease (COVID‐19) primarily affects the lungs and lower airways and may present as hypoxaemic respiratory failure requiring admission to an intensive care unit (ICU) for supportive treatment. Here, supplemental oxygen remains essential for COVID‐19 patient management, but the optimal dosage is not defined. We hypothesize that targeting an arterial partial pressure of oxygen of 8 kPa throughout ICU admission is superior to targeting 12 kPa.Methods: The Handling Oxygenation Targets in ICU patients with COVID‐19 (HOT‐COVID) trial, is an investigator‐initiated, pragmatic, multicentre, randomized, parallel‐group trial comparing a lower oxygenation target versus a higher oxygenation target in adult ICU patients with COVID‐19. The primary outcome is days alive without life‐support (use of mechanical ventilation, renal replacement therapy or vasoactive therapy) at day 90. Secondary outcomes are 90‐day and 1‐year mortality, serious adverse events in the ICU and days alive and out of hospital in the 90‐day period, health‐related quality‐of‐life at 1 year, and health economic analyses. One‐year follow‐up of cognitive and pulmonary function is planned in a subgroup of Danish patients. We will include 780 patients to detect or reject an absolute increase in days alive without life‐support of 7 days with an α of 5% and a β of 20%. An interim analysis is planned after 90‐day follow‐up of 390 patients.Conclusions: The HOT‐COVID trial will provide patient‐important data on the effect of two oxygenation targets in ICU patients with COVID‐19 and hypoxia. This protocol paper describes the background, design and statistical analysis plan for the trial.